{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:40:00Z","timestamp":1773369600905,"version":"3.50.1"},"reference-count":29,"publisher":"National Center for Global Health and Medicine (JST)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM Open"],"published-print":{"date-parts":[[2022,8,5]]},"DOI":"10.35772\/ghmo.2022.01002","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T22:09:31Z","timestamp":1647554971000},"page":"38-43","source":"Crossref","is-referenced-by-count":5,"title":["Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan"],"prefix":"10.35772","volume":"2","author":[{"given":"Satoshi","family":"Kutsuna","sequence":"first","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."},{"name":"Department of Infection Control, Graduate School of Medicine Faculty of Medicine, Osaka University, Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Saito","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Terada","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."},{"name":"Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomiteru","family":"Togano","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Satake","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Central Blood Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Matsubayashi","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Central Blood Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson Hirokazu","family":"Tsuno","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Kojima","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Central Blood Institute, Tokyo, Japan."},{"name":"Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Kuramitsu","sequence":"additional","affiliation":[{"name":"Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Tezuka","sequence":"additional","affiliation":[{"name":"Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Ikebe","sequence":"additional","affiliation":[{"name":"Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazu","family":"Okuma","sequence":"additional","affiliation":[{"name":"Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Shimanishi","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hangaishi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihito","family":"Ishizaka","sequence":"additional","affiliation":[{"name":"Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[{"name":"Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[{"name":"Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","unstructured":"1. World Health Organization. Weekly epidemiological update - 30 November 2021. <i>https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---30-november-2021<\/i> (accessed February 9, 2022)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kutsuna S. Coronavirus disease 2019 (COVID-19): research progress and clinical practice. Glob Health Med. 2020; 2:78-88.","DOI":"10.35772\/ghm.2020.01031"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, Pacanowski J, M\u00e9kinian A, Pirenne F, Tiberghien P, Calvez V, Humbrecht C, Marcelin AG, Lacombe K. Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin Infect Dis. 2021; 5;73:e1762-e1765.","DOI":"10.1093\/cid\/ciaa1474"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 17;145:599-609.","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979; 2:1216-1217.","DOI":"10.1016\/S0140-6736(79)92335-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007; 357:1450-1451.","DOI":"10.1056\/NEJMc070359"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. van Griensven J, Edwards T, de Lamballerie X, <i>et al.<\/i> Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016; 374:33-42.","DOI":"10.1056\/NEJMoa1511812"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24:44-46.","DOI":"10.1007\/s10096-004-1271-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Arabi Y, Balkhy H, Hajeer AH, <i>et al.<\/i> Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015; 4:709.","DOI":"10.1186\/s40064-015-1490-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ko JH, Seok H, Cho SY, <i>et al.<\/i> Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018; 23:617-622.","DOI":"10.3851\/IMP3243"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shen C, Wang Z, Zhao F, <i>et al.<\/i> Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020; 323:1582-1589.","DOI":"10.1001\/jama.2020.4783"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020; 371:m3939.","DOI":"10.1136\/bmj.m3939"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Joyner MJ, Carter RE, Senefeld JW, <i>et al.<\/i> Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021; 384:1015-1027.","DOI":"10.1056\/NEJMoa2031893"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Libster R, P\u00e9rez Marc G, Wappner D, <i>et al.<\/i> Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021; 384:610-618.","DOI":"10.1056\/NEJMc2104747"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Terada M, Kutsuna S, Togano T, <i>et al.<\/i> How we secured a COVID-19 convalescent plasma procurement scheme in Japan. Transfusion. 2021; 61:1998-2007.","DOI":"10.1111\/trf.16541"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nomoto H, Kutsuna S, Okuma K, <i>et al.<\/i> No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity. J Infect Chemother. 2021; 27:653-655.","DOI":"10.1016\/j.jiac.2021.01.004"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kutsuna S, Asai Y, Matsunaga A. Loss of anti-SARS-CoV-2 antibodies in mild Covid-19. N Engl J Med. 2020; 383:1695-1696.","DOI":"10.1056\/NEJMx200017"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kutsuna S, Asai Y, Matsunaga A, <i>et al.<\/i> Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. J Infect Chemother. 2021; 27:808-813.","DOI":"10.1016\/j.jiac.2021.01.006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Maeda K, Higashi-Kuwata N, Kinoshita N, Kutsuna S, Tsuchiya K, Hattori S, Matsuda K, Takamatsu Y, Gatanaga H, Oka S, Sugiyama H, Ohmagari N, Mitsuya H. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma. Sci Rep. 2021; 11:5563.","DOI":"10.1038\/s41598-021-84733-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hattori SI, Higashi-Kuwata N, Hayashi H, <i>et al.<\/i> A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun. 2021; 12:668.","DOI":"10.1038\/s41467-021-20900-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Joyner MJ, Bruno KA, Klassen SA, <i>et al.<\/i> Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020; 95:1888-1897.","DOI":"10.1016\/j.mayocp.2020.09.032"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Matsunaga N, Hayakawa K, Terada M, <i>et al.<\/i> Clinical epidemiology of hospitalized patients with COVID-19 in Japan: report of the COVID-19 Registry Japan. Clin Infect Dis. 2021; 73:e3677-e3689.","DOI":"10.1093\/cid\/ciaa1470"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Simonovich VA, Burgos Pratx LD, Scibona P, <i>et al.<\/i> A Randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021; 384:619-629.","DOI":"10.1056\/NEJMoa2031304"},{"key":"24","unstructured":"24. Sullivan DJ, Gebo KA, Shoham S, <i>et al.<\/i> Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma. medRxiv [Preprint]. 2021; 2021.12.10.21267485."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Korley FK, Durkalski-Mauldin V, Yeatts SD, <i>et al.<\/i> Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021; 385:1951-1960.","DOI":"10.1056\/NEJMoa2103784"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Takamatsu Y, Imai M, Maeda K, Nakajima N, Higashi-Kuwata N, Iwatsuki-Horimoto K , Ito M, Kiso M, Maemura T, Takeda Y, Omata K, Suzuki T, Kawaoka Y, Mitsuya H. Highly neutralizing COVID-19 convalescent plasmas potently block SARS-CoV-2 replication and pneumonia in Syrian hamsters. J Virol. 2022; 96:e0155121.","DOI":"10.1128\/jvi.01551-21"},{"key":"27","unstructured":"27. Weinreich DM, Sivapalasingam S, Norton T, <i>et al.<\/i> REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021; 385:e81."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Gupta A, Gonzalez-Rojas Y, Juarez E, <i>et al.<\/i> Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021; 385:1941-1950.","DOI":"10.1056\/NEJMoa2107934"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. N\u00e9ant N, Lingas G, Le Hingrat Q, <i>et al.<\/i> Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci U S A. 2021; 118:e2017962118.","DOI":"10.1073\/pnas.2017962118"}],"container-title":["GHM Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghmo\/2\/1\/2_2022.01002\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:04:43Z","timestamp":1715231083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghmo\/2\/1\/2_2022.01002\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.35772\/ghmo.2022.01002","relation":{},"ISSN":["2436-293X","2436-2956"],"issn-type":[{"value":"2436-293X","type":"print"},{"value":"2436-2956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"article-number":"2022.01002"}}